Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial

• Grégoire Stalder,
• Madeleine Suffiotti,
• Amandine Segot,
• Alessandra Noto,
• Giuseppe Pantaleo,
• Olivier Spertini,
• Michel Obeid

Affiliations

Grégoire Stalder

Service and Central Laboratory of Hematology, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne, Switzerland; Service of Hematology and Laboratory of Hematology, Institut Central des Hôpitaux, Hôpital du Valais, Av. du Grand-Champsec 86, CH-1951 Sion, Switzerland; University of Lausanne, Lausanne

Madeleine Suffiotti

Division of Immunology and Allergy, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne

Amandine Segot

Service and Central Laboratory of Hematology, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne

Alessandra Noto

Division of Immunology and Allergy, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne

Giuseppe Pantaleo

University of Lausanne, Lausanne, Switzerland; Division of Immunology and Allergy, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne

Olivier Spertini

Service and Central Laboratory of Hematology, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne, Switzerland; University of Lausanne, Lausanne

Michel Obeid

University of Lausanne, Lausanne, Switzerland; Division of Immunology and Allergy, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne